These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 26980302)

  • 1. Tipping the Balance: Hepatotoxicity and the 4 Apical Key Events of Hepatic Steatosis.
    Angrish MM; Kaiser JP; McQueen CA; Chorley BN
    Toxicol Sci; 2016 Apr; 150(2):261-8. PubMed ID: 26980302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of hepatic fibrosis with liver microsomal triglyceride transfer protein deletion in liver fatty acid binding protein null mice.
    Newberry EP; Xie Y; Kennedy SM; Graham MJ; Crooke RM; Jiang H; Chen A; Ory DS; Davidson NO
    Hepatology; 2017 Mar; 65(3):836-852. PubMed ID: 27862118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells.
    Rogue A; Anthérieu S; Vluggens A; Umbdenstock T; Claude N; de la Moureyre-Spire C; Weaver RJ; Guillouzo A
    Toxicol Appl Pharmacol; 2014 Apr; 276(1):73-81. PubMed ID: 24534255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roles of adipose restriction and metabolic factors in progression of steatosis to steatohepatitis in obese, diabetic mice.
    Larter CZ; Yeh MM; Van Rooyen DM; Teoh NC; Brooling J; Hou JY; Williams J; Clyne M; Nolan CJ; Farrell GC
    J Gastroenterol Hepatol; 2009 Oct; 24(10):1658-68. PubMed ID: 19788606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
    Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
    Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonalcoholic fatty liver disease: molecular mechanisms for the hepatic steatosis.
    Koo SH
    Clin Mol Hepatol; 2013 Sep; 19(3):210-5. PubMed ID: 24133660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation.
    Reddy JK; Rao MS
    Am J Physiol Gastrointest Liver Physiol; 2006 May; 290(5):G852-8. PubMed ID: 16603729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid metabolism and liver inflammation. I. Hepatic fatty acid uptake: possible role in steatosis.
    Bradbury MW
    Am J Physiol Gastrointest Liver Physiol; 2006 Feb; 290(2):G194-8. PubMed ID: 16407588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PFOS-induced hepatic steatosis, the mechanistic actions on β-oxidation and lipid transport.
    Wan HT; Zhao YG; Wei X; Hui KY; Giesy JP; Wong CK
    Biochim Biophys Acta; 2012 Jul; 1820(7):1092-101. PubMed ID: 22484034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic role of niacin in the prevention and regression of hepatic steatosis in rat model of nonalcoholic fatty liver disease.
    Ganji SH; Kukes GD; Lambrecht N; Kashyap ML; Kamanna VS
    Am J Physiol Gastrointest Liver Physiol; 2014 Feb; 306(4):G320-7. PubMed ID: 24356885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxymatrine attenuates hepatic steatosis in non-alcoholic fatty liver disease rats fed with high fructose diet through inhibition of sterol regulatory element binding transcription factor 1 (Srebf1) and activation of peroxisome proliferator activated receptor alpha (Pparα).
    Shi LJ; Shi L; Song GY; Zhang HF; Hu ZJ; Wang C; Zhang DH
    Eur J Pharmacol; 2013 Aug; 714(1-3):89-95. PubMed ID: 23791610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Editor's Highlight: Mechanistic Toxicity Tests Based on an Adverse Outcome Pathway Network for Hepatic Steatosis.
    Angrish MM; McQueen CA; Cohen-Hubal E; Bruno M; Ge Y; Chorley BN
    Toxicol Sci; 2017 Sep; 159(1):159-169. PubMed ID: 28903485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis.
    Yamaguchi K; Yang L; McCall S; Huang J; Yu XX; Pandey SK; Bhanot S; Monia BP; Li YX; Diehl AM
    Hepatology; 2007 Jun; 45(6):1366-74. PubMed ID: 17476695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered lipid metabolism in Hfe-knockout mice promotes severe NAFLD and early fibrosis.
    Tan TC; Crawford DH; Jaskowski LA; Murphy TM; Heritage ML; Subramaniam VN; Clouston AD; Anderson GJ; Fletcher LM
    Am J Physiol Gastrointest Liver Physiol; 2011 Nov; 301(5):G865-76. PubMed ID: 21817060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Putative mechanisms of environmental chemical-induced steatosis.
    Kaiser JP; Lipscomb JC; Wesselkamper SC
    Int J Toxicol; 2012; 31(6):551-63. PubMed ID: 23197488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitamin D attenuates high fat diet-induced hepatic steatosis in rats by modulating lipid metabolism.
    Yin Y; Yu Z; Xia M; Luo X; Lu X; Ling W
    Eur J Clin Invest; 2012 Nov; 42(11):1189-96. PubMed ID: 22958216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A theoretical study of lipid accumulation in the liver-implications for nonalcoholic fatty liver disease.
    Schleicher J; Guthke R; Dahmen U; Dirsch O; Holzhuetter HG; Schuster S
    Biochim Biophys Acta; 2014 Jan; 1841(1):62-9. PubMed ID: 23999488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic lipid metabolism and non-alcoholic fatty liver disease.
    Tessari P; Coracina A; Cosma A; Tiengo A
    Nutr Metab Cardiovasc Dis; 2009 May; 19(4):291-302. PubMed ID: 19359149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-Induced Fatty Liver Disease (DIFLD): A Comprehensive Analysis of Clinical, Biochemical, and Histopathological Data for Mechanisms Identification and Consistency with Current Adverse Outcome Pathways.
    López-Pascual E; Rienda I; Perez-Rojas J; Rapisarda A; Garcia-Llorens G; Jover R; Castell JV
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases: a four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis.
    Wanless IR; Shiota K
    Semin Liver Dis; 2004 Feb; 24(1):99-106. PubMed ID: 15085490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.